Navigation Links
Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA

the BiTE molecule targeting EphA2 killed tumor cells at dose levels considerably below those required by classical monoclonal antibody-based therapies in in vivo and in vitro proof-of-concept studies.

"The EphA2 and CEA antigens are the focus of ongoing preclinical research within MedImmune's broad pipeline of potential treatments for cancer," said Peter Kiener, MedImmune's Senior Vice President, Research. "Both have been implicated in the growth and survival of a range of tumor types, and we are encouraged by the preclinical study results to date with these two highly potent BiTE molecules."

About BiTE(R) Molecules

BiTE molecules are a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T cells, the body's most potent killer cells, to act against cancer cells. MT103/MEDI-538, a BiTE molecule targeting the B cell antigen CD19, provided clinical proof-of-concept for the BiTE platform technology, as presented at the last meeting of the American Society for Hematology. In an ongoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy-refractory non-Hodgkins lymphoma patients.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
5. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
9. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
10. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
11. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
Post Your Comments:
(Date:7/23/2008)...Company Focused on IND-Enabling Work with Protein ...athway of Complement System, CAMBRIDGE, Mass., Ju...day announced it has initiated a corporate growth ..., as chief executive officer and the,establishment...ker succeeds,Woodruff Emlen, M.D., a co-founder of...
(Date:7/22/2008)...- Strong efficacy results from a multi-center 293-...com , Toronto Stock Exchange Symbol: CYT, MONTRE...echnologies,Inc., the global leader in cryotherapy...unced that results previously presented from three...roduct, Arctic Front(R),were published earlier to...
(Date:7/22/2008)...Latest awards under Therapeutics Development Initi...rations to 23; next deadline January 20,2009, NE... of its mission to,speed delivery of transformativ...he Michael J. Fox Foundation for Parkinson,s Resea...ix industry research teams. The awards,were grante...
(Date:7/22/2008)...tudy Demonstrates Feasibility and Efficacy of Trea...y Liver Cancer, SAN FRANCISCO, and YONGIN-SI, Sou...San Francisco, CA and Ottawa, Ontario), and its So...day that novel findings from,a Phase I clinical tr...nstrated that the product was well-tolerated and r...
Breaking Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Psoriasis Study Showing Increased Risk of Death Underscores Need for More Research Group Says 8476 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 1MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 2MedcomSoft Receives 2007s 22Best in KLAS 22 EMR Ranking 281 5 Physicians 29 8472 3Synthetech Earns National Recognition for Performance Improvement Program 2270 1Synthetech Earns National Recognition for Performance Improvement Program 2270 2Synthetech Earns National Recognition for Performance Improvement Program 2270 3Researchers hope to provide chronic fatigue syndrome answers 8470 1Researchers hope to provide chronic fatigue syndrome answers 8470 2
...History Highlighted in AACR Cancer Journal , AUSTI...Therapeutics, Inc. (NASDAQ:INGN) announced today t...nical benefit of its lead product,Advexin in a pat...,Li-Fraumeni Syndrome (LFS), a genetic disorder ch...r suppressor gene. This is the,first reported trea...
...LLE, Md.--(BUSINESS WIRE)--May 30, 2007 - Rexahn,P...tical company,dedicated to the discovery, developm...s for cancer, central nervous system disorders,se...day announced,that Dr. John Marshall, Principal In...y,s lead cancer compound RX-0201 (Archexin),will ...
Other Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4
(Date:7/25/2008)...ne is supporting the US Department of Defense and ...olden Phoenix. Operation Golden Phoenix is a, fo...designed to assist, federal, state and local agenc...enarios. Dataline is providing a vital, ad-hoc, se...dical use during the exercise., NORFOLK, Va., Jul...
(Date:7/25/2008)...HAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Pha...rmaceutical company, today announced that it,has l... antiarrhythmic,indicated for the treatment and pr...illation and hemodynamically unstable ventricular,...gular heart beat.,Sagent,s amiodarone HCl injectio...
(Date:7/25/2008)...finds fluid back-up in esophagus can cause immune ...thDay News) -- The first evidence linking gastroes... discovered by Duke University Medical Center rese...tions was first noted in the 1970s, and since then... percent of asthma patients also experience GERD s...
(Date:7/25/2008)... Whether you are an Olympian, P...ior, there are Five Things You Need to Know about ...I.S.C. Spine and Sports Center , ...08 -- America,s premier athletes are heading to Be...oning and sacrifice in the hopes of capturing an O...
Breaking Medicine News(10 mins):Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
... Industries Ltd today said it has acquired a signi...ary of US-based indigene Pharma Inc// , for an und...iopharmaceuticals, has been in the business of bot... healthcare products. Commenting on the strategic...
...discovery may help treat stroke-affected humans Ne...s recover after a stroke by stimulating a protein/...pes about the possibility of repairing the human b...h as stroke or spinal-cord damages. The findings ...
...ciate Health Minister Jim Anderton said that the G... people in all age groups//. New Zealand has a ve...given to bring down youth suicide rates. According...ms in 2003 were aged 25 or older. Suicide rates am...
...archers have concluded that earlier a deaf child r...r spoken language skills, sentence formation and u...deaf but used cochlear implants, able to hear part...he right time to make use of it. In contrast, a c...
Other Medicine News:Health News:Earlier the Cochlear Implants Used Better the Speech 2Health News:Earlier the Cochlear Implants Used Better the Speech 3
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: